BackIdera Pharmaceuticals Overview

Idera Pharmaceuticals Common Stock

Track Idera Pharmaceuticals's common stock ($8K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$8000.00
84.91% YoYΔ $-45000.00 vs prior year quarter

Peer average / median

Loading

Idera Pharmaceuticals Common Stock History

Loading

Idera Pharmaceuticals vs. peers: Common Stock Comparison

Loading

Idera Pharmaceuticals Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Idera Pharmaceuticals (IDRA) FAQ

As of the most recent data (March 2023), IDRA shows a common stock of $8K. That compares with $53K in the prior-year period — down 84.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IDRA's common stock is now $8K (was $53K) — a 84.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Idera Pharmaceuticals is outperforming or lagging.

Tracking IDRA's common stock over time shows whether Idera Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $8K That compares with $53K in the prior-year period — down 84.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Idera Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $8K) with ownership activity and broader fundamentals.

Idera Pharmaceuticals's common stock is $8K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.